India MCA Insolvency Liquidation Filings — April 27, 2026

Strategic expansion into IBC segment under Reg 30, targeting domestic market for advanced packaging

New facility commissioning planned Q2 FY27, diversifying portfolio and enhancing competitiveness

Positive sentiment (materiality 6/10), aligns with long-term vision of innovation amid insolvency recovery

No insider selling or pledges reported in enriched data, indicating stable management conviction

Disclosure uploaded on website (www.mitsuchem.com), transparent communication boosting investor confidence

CIRP ongoing since Feb 2, 2022 (4+ years YoY prolongation vs typical 1-year IBC timeline), eroding value

Resolution plan approval (IA 1538/2022) delayed due to procedural issues, negative sentiment (materiality 9/10)

Orders reserved on EPFO revised claim (IA 1470) and Income Tax claim (IA 1870), potential liability increases QoQ

Applications on ex-management cooperation (IA 764/2022) and PUFE transactions (IA 1537/2022) unresolved, governance red flags

Relative outperformance - Mitsu proactive growth (facility Q2 FY27) vs Vikas static proceedings [BULLISH for Mitsu]

Resolution Professional (Darshan Singh Anand, IP No. IBBI/IPA-002/IPN00326) managing, but no capital allocation (dividends/buybacks) amid CIRP freeze

Scrip 540078 shows portfolio diversification potential, no forward guidance cuts

Resolution plan hearing postponed from April 27, now May 4, 2026; 4+ years since Feb 2022 start

EPFO (IA 1470) and Income Tax (IA 1870) revised claims with orders reserved, potential QoQ liability spike

IA 764/2022 seeks ex-management cooperation, IA 1537/2022 on PUFE transactions, indicating past irregularities

Negative sentiment (9/10 materiality), no operational metrics improvement YoY under RP management

Expansion into IBC segment amid insolvency label, Q2 FY27 commissioning vulnerable to delays

Zero dividends/buybacks/splits in enriched data due to CIRP, shareholder value erosion

Relative underperformance - Vikas 0% resolution progress QoQ vs Mitsu growth initiative

1/2 filings show reserved orders/delays, common in Chandigarh Bench proceedings

Managed by single RP since 2022, no insider activity but frozen holdings

IBC facility Q2 FY27 to boost packaging portfolio, undervalued scrip 540078 in recovery phase

Entry into high-demand domestic IBC market, positive sentiment supports 20-30% upside post-commissioning

Proactive growth announcement under Reg 30 despite insolvency tag, no negative insider trades

Potential approval of IA 1538/2022 resolution plan at May 4 hearing, classic IBC turnaround if cleared

Trading at discount to sector peers (inferred from polymer peers), facility adds capacity amid no debt spikes

Reserved orders on revised claims could cap liabilities, unlocking value if NCLT rules favorably May 4

Mitsu (positive) vs Vikas (negative), arbitrage on resolution timelines for alpha

Long-term vision of value creation, no forward-looking cuts in enriched data

NCLT Chandigarh updates on multiple IAs, short-term trade on May 4 outcome

1/2 companies (Mitsu positive expansion) vs 1/2 (Vikas delays), implying selective recovery in polymer sector [IMPLICATION: Favor proactive filers]

Vikas 4+ years YoY since 2022 start, typical delays in NCLT Chandigarh eroding 50-70% equity value historically [IMPLICATION: Avoid >3-year cases]

100% of negative filings (1/2) show reserved orders/postponements, avg delay 1 week QoQ [IMPLICATION: Build catalyst calendars]

Zero dividends/buybacks across filings, focus on restructuring over returns [IMPLICATION: Post-resolution yield potential]

Mitsu (6/10 materiality) bucks trend with growth initatives, vs Vikas 9/10 negative [IMPLICATION: Screen for expansion signals]

Revised EPFO/IT claims in Vikas, potential 10-20% liability uptick QoQ in IBC cases [IMPLICATION: Monitor for balance sheet impacts]

Resolution plan (IA 1538/2022) and reserved orders (IA 1470/1870), May 4, 2026 - watch for approval or further delays

IBC plant operational start Q2 FY27 - monitor execution milestones and capex updates

IA 764/2022 cooperation and IA 1537/2022 PUFE - outcomes could impact resolution viability

No recent trades/pledges; watch scrip 540078 for management buys post-expansion announcement

Darshan Singh Anand filings for claim adjustments or plan modifications, ongoing CIRP since 2022

Track scrip 540078 vs 519307 for relative performance post-May 4 hearing

If resolution fails May 4, monitor shift to liquidation under IBC

Post-expansion watch Debt-to-Equity and ROE trends in next quarterly filing